JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graham, M. J.
Right arrow Articles by Crooke, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graham, M. J.
Right arrow Articles by Crooke, R. M.

Vol. 286, Issue 1, 447-458, July 1998

In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration

Mark J. Graham, Stanley T. Crooke, David K. Monteith, Scott R. Cooper, Kristina M. Lemonidis, Kim K. Stecker, Michael J. Martin and Rosanne M. Crooke

Isis Pharmaceuticals, Inc., Carlbad Research Center, Carlsbad, California

In the rat, the liver represents a major site of phosphorothioate oligodeoxynucleotide deposition after i.v. administration. For this reason, we examined the intracellular fate of ISIS 1082, a 21-base heterosequence phosphorothioate oligodeoxynucleotide, isolated from parenchymal and nonparenchymal cell types after systemic dosing using established perfusion and separation techniques followed by CGE. Isolated cells were further fractionated into nuclear, cytosolic and membrane constituents to assess the intracellular localization, distribution and metabolic profiles as a function of time and dose. After a 10-mg/kg i.v. bolus, intracellular drug levels where maximal after 8 hr and diminished significantly thereafter, suggesting an active efflux mechanism or metabolism. Nonparenchymal (i.e., Kupffer and endothelial) cells contained approximately 80% of the total organ cellular dose, and this was equivalently distributed between the two cell types, while the remaining 20% was associated with hepatocytes. Nonparenchymal cells contained abundant nuclear, cytosolic and membrane drug levels over a wide dose range. In contrast, at doses of less than 25 mg/kg, hepatocytes contained significantly less drug with no detectable nuclear-association. Doses at or above 25 mg/kg appeared to saturate nonparenchymal cell types, whereas hepatocytes continued to accumulate drug in all cellular compartments, including the nucleus. Our results suggest that although pharmacokinetic parameters vary as a function of hepatic cell type, significant intracellular delivery can be readily achieved in the liver after systemic administration.

0022-3565/98/2861-0447$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
L. M. Greenberger, I. D. Horak, D. Filpula, P. Sapra, M. Westergaard, H. F. Frydenlund, C. Albaek, H. Schroder, and H. Orum
A RNA antagonist of hypoxia-inducible factor-1{alpha}, EZN-2968, inhibits tumor cell growth
Mol. Cancer Ther., November 1, 2008; 7(11): 3598 - 3608.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
V. T. Samuel, C. S. Choi, T. G. Phillips, A. J. Romanelli, J. G. Geisler, S. Bhanot, R. McKay, B. Monia, J. R. Shutter, R. A. Lindberg, et al.
Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action.
Diabetes, July 1, 2006; 55(7): 2042 - 2050.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R. M. Crooke, M. J. Graham, K. M. Lemonidis, C. P. Whipple, S. Koo, and R. J. Perera
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
J. Lipid Res., May 1, 2005; 46(5): 872 - 884.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
Y. Liang, M. C. Osborne, B. P. Monia, S. Bhanot, W. A. Gaarde, C. Reed, P. She, T. L. Jetton, and K. T. Demarest
Reduction in Glucagon Receptor Expression by an Antisense Oligonucleotide Ameliorates Diabetic Syndrome in db/db Mice
Diabetes, February 1, 2004; 53(2): 410 - 417.
[Abstract] [Full Text]

Home page
 Nucleic Acids ResHome page
D. Husken, F. Asselbergs, B. Kinzel, F. Natt, J. Weiler, P. Martin, R. Haner, and J. Hall
mRNA fusion constructs serve in a general cell-based assay to profile oligonucleotide activity
Nucleic Acids Res., September 1, 2003; 31(17): e102 - e102.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
S. P. Henry, D.K. Monteith, J.E. Matson, B.H. Mathison, K.S. Loveday, R.A. Winegar, J.E. Matson, P.S. Lee, E.S. Riccio, J.P. Bakke, et al.
Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide
Mutagenesis, May 1, 2002; 17(3): 201 - 209.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Z. Yu, H. Zhang, R. S. Geary, M. Graham, L. Masarjian, K. Lemonidis, R. Crooke, N. M. Dean, and A. A. Levin
Pharmacokinetics and Pharmacodynamics of an Antisense Phosphorothioate Oligonucleotide Targeting Fas mRNA in Mice
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 388 - 395.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. S. Geary, T. A. Watanabe, L. Truong, S. Freier, E. A. Lesnik, N. B. Sioufi, H. Sasmor, M. Manoharan, and A. A. Levin
Pharmacokinetic Properties of 2'-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 890 - 897.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. S. Geary, O. Khatsenko, K. Bunker, R. Crooke, M. Moore, T. Burckin, L. Truong, H. Sasmor, and A. A. Levin
Absolute Bioavailability of 2'-O-(2-Methoxyethyl)-Modified Antisense Oligonucleotides following Intraduodenal Instillation in Rats
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 898 - 904.
[Abstract] [Full Text]

Home page
 Pharmacol. Rev.Home page
L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach
Catalytic Nucleic Acids: From Lab to Applications
Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
T. A. Vickers, J. R. Wyatt, and S. M. Freier
Effects of RNA secondary structure on cellular antisense activity
Nucleic Acids Res., March 15, 2000; 28(6): 1340 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Butler, R. M. Crooke, M. J. Graham, K. M. Lemonidis, M. Lougheed, S. F. Murray, D. Witchell, U. Steinbrecher, and C. F. Bennett
Phosphorothioate Oligodeoxynucleotides Distribute Similarly in Class A Scavenger Receptor Knockout and Wild-Type Mice
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 489 - 496.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. M. Crooke, M. J. Graham, M. J. Martin, K. M. Lemonidis, T. Wyrzykiewiecz, and L. L. Cummins
Metabolism of Antisense Oligonucleotides in Rat Liver Homogenates
J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 140 - 149.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
G. Schmajuk, H. Sierakowska, and R. Kole
Antisense Oligonucleotides with Different Backbones. MODIFICATION OF SPLICING PATHWAYS AND EFFICACY OF UPTAKE
J. Biol. Chem., July 30, 1999; 274(31): 21783 - 21789.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.